|

Effects of Normobaric Hypoxic Training in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

RECRUITINGN/ASponsored by University of Trieste
Actively Recruiting
PhaseN/A
SponsorUniversity of Trieste
Started2025-09-01
Est. completion2026-05
Eligibility
Age18 Years – 50 Years
Healthy vol.Accepted

Summary

Altitude training has been suggested to be of potential support to improve some chronic clinical conditions, especially metabolic conditions. Normobaric hypoxia represents a promising system to simulate altitude training, and its efficacy and safety have been suggested in different conditions, including diabetes, obesity and hypertension. Metabolic dysfunction-associated steatotic liver disease (MASLD) can characterized by metabolic alterations (including altered body composition, lipid and glycemic profile, etc.), and might benefit from aerobic training performed in simulated altitude training (i.e., normobaric hypoxia). Mild altitude training will be proposed (equal to about 2'500 m, 15% FiO2) and compared to a sham normobaric normoxia condition, during an 8-week 3 or 2 times per week 1-h aerobic training (walking) at 60-65% of maximum heart rate (HRmax). Cardiorespiratory fitness, body composition, and metabolic profile will be investigated.

Eligibility

Age: 18 Years – 50 YearsHealthy volunteers accepted
Inclusion Criteria:

* Being diagnosed with MASLD from at the least 3 years
* BMI \> 26 kg/m2
* Being sedentary

Exclusion Criteria:

* Cardiovascular, respiratory, renal complications
* Hypertension
* COPD
* Previous history of acute mountain sickness or altitude-associated symptoms
* Females only: pregnancy or breastfeeding

Conditions3

Liver DiseaseMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseNormobaric Hypoxia

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.